Skip to Content
Merck
All Photos(1)

Documents

1479304

USP

Oseltamivir phosphate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid ethyl ester phosphate salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C16H28N2O4 ·H3PO4
CAS Number:
204255-11-8
Molecular Weight:
410.40
MDL number:
MFCD08059548
UNSPSC Code:
41116107
PubChem Substance ID:
329750621
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

oseltamivir

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1

InChI

1S/C16H28N2O4.H3O4P/c1-5-12(6-2)22-14-9-11(16(20)21-7-3)8-13(17)15(14)18-10(4)19;1-5(2,3)4/h9,12-15H,5-8,17H2,1-4H3,(H,18,19);(H3,1,2,3,4)/t13-,14+,15+;/m0./s1

InChI key

PGZUMBJQJWIWGJ-ONAKXNSWSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application


  • Neuraminidase Inhibition by Oseltamivir Phosphate: Oseltamivir phosphate′s mechanism as a neuraminidase inhibitor was highlighted in a study examining its effect on virus-neutralizing antibodies in influenza A-infected mice, demonstrating its impact on dosage and scheduling for effective flu treatment (Mikušová et al., 2022).

  • Oseltamivir Phosphate in Lung Cancer Research: Research explored the use of oseltamivir phosphate loaded into pegylated-Eudragit nanoparticles for lung cancer therapy, focusing on characterization, prolonged release, cytotoxicity profile, apoptosis pathways, and the anti-angiogenic effect, thereby expanding its application beyond traditional antiviral uses (Yurtdaş-Kırımlıoğlu et al., 2022).

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317,H319,H412

Hazard Classifications

Aquatic Chronic 3 - Eye Irrit. 2 - Skin Sens. 1

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 8

1 of 8

Peramivir trihydrate ≥98% (HPLC)

Sigma-Aldrich

SML2486

Peramivir trihydrate

Zanamivir for assay European Pharmacopoeia (EP) Reference Standard

Y0001702

Zanamivir for assay

Zanamivir ≥98% (HPLC)

Sigma-Aldrich

SML0492

Zanamivir

Ribavirin antiviral

Sigma-Aldrich

R9644

Ribavirin

Cyclosporine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1092

Cyclosporine

Mupirocin ≥92% (HPLC), powder

Sigma-Aldrich

M7694

Mupirocin

Ritonavir ≥98% (HPLC)

Sigma-Aldrich

SML0491

Ritonavir

Mucin from bovine submaxillary glands Type I-S

Sigma-Aldrich

M3895

Mucin from bovine submaxillary glands

Ding Yuan Oh et al.
The Journal of antimicrobial chemotherapy, 69(9), 2458-2469 (2014-05-21)
The emergence of the pandemic influenza A(H1N1)pdm09 virus in 2009 saw a significant increase in the therapeutic and prophylactic use of neuraminidase inhibitors (NAIs) to mitigate the impact of this highly transmissible virus. Prior to the pandemic, many countries stockpiled
Henju Marjuki et al.
The Journal of infectious diseases, 210(3), 435-440 (2014-02-27)
Human infections caused by avian influenza A virus type subtype H7N9 have been associated with substantial morbidity and mortality. Emergence of virus variants carrying markers of decreased susceptibility to neuraminidase inhibitors was reported. Here we show that DAS181 (Fludase), an
Henju Marjuki et al.
Journal of virology, 89(10), 5419-5426 (2015-03-06)
Human infections by avian influenza A(H7N9) virus entail substantial morbidity and mortality. Treatment of infected patients with the neuraminidase (NA) inhibitor oseltamivir was associated with emergence of viruses carrying NA substitutions. In the NA inhibition (NI) assay, R292K conferred highly
Isabelle Marois et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 29(3), 973-987 (2014-11-22)
The clinical benefits of oseltamivir (Tamiflu) are well established, but the effects of antiviral treatment on the immune response are poorly understood. By use of flow cytometric analyses and the mouse model, we thoroughly investigated the impact of such a
Eric J Stavale et al.
PloS one, 10(3), e0121662-e0121662 (2015-03-19)
Our lead iminosugar analog called UV-4 or N-(9-methoxynonyl)-1-deoxynojirimycin inhibits activity of endoplasmic reticulum (ER) α-glucosidases I and II and is a potent, host-targeted antiviral candidate. The mechanism of action for the antiviral activity of iminosugars is proposed to be inhibition
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service